Market Analysis on Primary Immunodeficiency Disorders Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Primary Immunodeficiency Disorders Market from 2024 to 2025?
In recent years, there has been robust growth in the primary immunodeficiency disorders market size. Its expansion is anticipated to proceed from $6.84 billion in 2024 to $7.32 billion in 2025, presenting a compound annual growth rate (CAGR) of 7.0%. The expansion during the historic period is a result of an increase in cases of primary immunodeficiency disorders, enhanced awareness among healthcare providers, a rise in demand for successful treatment, increased research budget, and an escalating emphasis on pediatric care.
What Is the Projected Market Size of the Primary Immunodeficiency Disorders Market?
In the coming years, a substantial surge is anticipated in the spectrum of primary immunodeficiency disorders, propelling the market to an estimated worth of $9.51 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%. The upward trend during the forecast period is attributed to factors including broader acceptance of subcutaneous therapies, improved access to health care, solid research and development initiatives, a rising need for effective treatment modes and a growing demand for immunoglobulin replacement therapy. The projection period is expected to witness notable trends such as progress in biotechnology, innovative strategies in gene therapies and biologics, breakthroughs in genetic testing and personalized medicine, evolution in gene therapy, and strides in genetic examinations.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23483&type=smp
Who are the Major Competitors in the Primary Immunodeficiency Disorders Market Outlook?
Major companies operating in the primary immunodeficiency disorders market are Pfizer Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceuticals, CSL Behring, Baxter International Inc., Grifols SA, Octapharma, Kedrion Biopharma, Miltenyi Biotec, LFB Group, Clinigen Limited, ADMA Biologics Inc., Bio Products Laboratory Ltd, BD Biosciences, Cellectis SA, Florencia Healthcare, X4 Pharmaceuticals Inc., Amber Lifesciences, bluebird bio Inc., Chengdu Rongsheng Pharmaceutical Co Ltd.
What Is Fueling Growth in the Primary Immunodeficiency Disorders Market?
The increase in autoimmune diseases is predicted to stimulate the expansion of the primary immunodeficiency disorders market. When the immune system erroneously attacks the body’s healthy cells and tissues, viewing them as foreign invaders, it’s classified as an autoimmune disease. This unusual reaction causes inflammation and damage to various organs and systems. The spike in autoimmune diseases is due to an intricate combination of environmental factors, genetic propensities, and changes in lifestyle. Autoimmune diseases can trigger primary immunodeficiency disorders by interfering with immune regulation and targeting immune cells, resulting in impaired or dysfunctional immune responses. For example, Versorgungsatlas.de, a Germany-based interactive online platform, revealed in November 2024 that in 2022, out of 73,241,305 insured people, 6,304,340 were diagnosed with at least one autoimmune disease, yielding a raw prevalence rate of 8.61%. Hence, the rising prevalence of autoimmune diseases is propelling the expansion of the primary immunodeficiency disorders market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23483&type=smp
Which Primary Immunodeficiency Disorders Market Segments Are Growing the Fastest?
The primary immunodeficiency disorders market covered in this report is segmented –
1) By Disease: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Other Diseases
2) By Treatment: Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell And Bone Marrow Transplantation, Gene Therapy, Other Treatments
3) By Diagnostic Type: Genetic Testing, Blood Testing, Flow Cytometry, Other Diagnostic Types
4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Research Institutions
Subsegments:
1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID), IgA Deficiency, IgG Subclass Deficiency, Specific Antibody Deficiency
2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID), T-Cell Deficiency, DiGeorge Syndrome, Wiskott-Aldrich Syndrome
3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD), Complement Deficiencies, Toll-like Receptor Deficiencies, Chediak-Higashi Syndrome
4) By Other Diseases: Hyper IgM Syndrome, Hyper IgE Syndrome, Ataxia-Telangiectasia, Combined Immunodeficiencies With Syndromic Features
Which Industry Trends Are Shaping the Future of the Primary Immunodeficiency Disorders Market?
Leading firms in the primary immunodeficiency disorders market are concentrating on creating cutting-edge therapies, including intravenous immunoglobulin therapy, in order to improve patient results by enhancing immune functionality. Intravenous immunoglobulin (IVIG) therapy, a process where antibodies from donor plasma are directly injected into the patient’s bloodstream via an IV. For instance, in June 2024, Grifols, a Spain-based healthcare company, secured FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This newly formulated, sugar-free, ready-to-use IgG solution, which is extracted from human blood plasma, is meant to be administered intravenously. Approved for use in the U.S. as a substitution therapy for primary antibody deficiency syndromes, Yimmugo provides antibody replacement to support people with immune system deficiencies. The introduction of this therapy boosts Grifols’ line-up of plasma-derived treatments by providing a safer and more efficient option to ward off infections.
Access The Full Report Here:
Which Countries Are Leading the Primary Immunodeficiency Disorders Market?
North America was the largest region in the primary immunodeficiency disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary immunodeficiency disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23483
This Report Delivers Insight On:
1. How big is the primary immunodeficiency disorders market, and how is it changing globally?
2. Who are the major companies in the primary immunodeficiency disorders market, and how are they performing?
3. What are the key opportunities and risks in the primary immunodeficiency disorders market right now?
4. Which products or customer segments are growing the most in the primary immunodeficiency disorders market?
5. What factors are helping or slowing down the growth of the primary immunodeficiency disorders market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
